ESLAW

Estrella Immunopharma, Inc.

ESLAW · CIK 1844417 · Annual (10-K) · Last 3 years

Financial Trends

Revenue
20212024
Net Income−$7M
20212024
Operating CF−$16M
20212024
Free Cash Flow
20212024

Income Statement

MetricFY 2024↕FY 2022↕FY 2021↕
Revenue———
Cost of Revenue———
Gross Profit———
R&D Expense$0.0B——
SG&A Expense———
Operating Income$-0.0B$-0.0B$-0.0B
Net Income$-0.0B$-0.0B$-0.0B
EPS (Basic)$-0.27——
EPS (Diluted)$-0.27——

Balance Sheet

MetricFY 2024↕FY 2022↕FY 2021↕
Total Assets$0.0B$0.0B$0.0B
Current Assets$0.0B$0.0B$0.0B
Cash & Equivalents$0.0B$0.0B$0.0B
Total Liabilities$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B
Stockholders' Equity$0.0B$-0.0B$-0.0B

Cash Flow Statement

MetricFY 2024↕FY 2022↕FY 2021↕
Operating Cash Flow$-0.0B$-0.0B$-0.0B
Investing Cash Flow$0.0B$0.0B$-0.0B
Capital Expenditures———
Financing Cash Flow$0.0B$-0.0B$0.0B
← Companies